Want to see IN:WOCKPHARMA full AI Analyst Report?
Top Page
Wockhardt Limited
(WOCKPHARMA)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹2,170.00
▲(54.39% Upside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by improving but still inconsistent financial performance (profitability recovery offset by volatile margins and uneven free cash flow). Technicals add support due to a clear uptrend and positive momentum, while the overall score is held back by a rich valuation (high P/E) and no dividend yield data.
Positive Factors
Revenue recovery
Recent revenue growth and a return to positive net income indicate that the business is recovering from its prior downturn. If this improvement persists, stronger sales can support operating leverage, product investment, and improved financial resilience over the next several quarters.
Negative Factors
Long history of losses and volatile margins
The FY2026 recovery has not yet established a consistent earnings record because several preceding years contained losses and significant operating-profit swings. Persistent margin instability can limit reinvestment capacity, reduce predictability for stakeholders, and weaken the durability of the current profit recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue recovery
Recent revenue growth and a return to positive net income indicate that the business is recovering from its prior downturn. If this improvement persists, stronger sales can support operating leverage, product investment, and improved financial resilience over the next several quarters.
Read all positive factors
Wockhardt Limited (WOCKPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹339.07B
Dividend Yield1.27%
Average Volume (3M)91.14K
Price to Earnings (P/E)83.3
Beta (1Y)1.23
Revenue Growth18.37%
EPS GrowthN/A
CountryIN
Employees2,564
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)25.16
Shares Outstanding162,485,570
10 Day Avg. Volume149,958
30 Day Avg. Volume91,140
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wockhardt Limited Business Overview & Revenue Model
Company Description
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuti...
How the Company Makes Money
Wockhardt makes money primarily by selling pharmaceutical products and related services across domestic and international markets. Key revenue streams typically include: (1) Finished dosage formulations (branded and/or generics): revenue generated...
Wockhardt Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
48
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.64B | 33.73B | 30.35B | 28.30B | 26.57B | 32.30B |
| Gross Profit | 16.39B | 12.89B | 18.26B | 15.98B | 14.85B | 18.81B |
| EBITDA | 8.71B | 6.78B | 3.60B | 1.38B | 420.00M | 2.26B |
| Net Income | 4.09B | 2.13B | -470.00M | -4.63B | -5.59B | -2.44B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 86.15B | 81.35B | 76.49B | 76.83B | 82.43B |
| Cash, Cash Equivalents and Short-Term Investments | 6.80B | 6.62B | 6.13B | 5.23B | 1.50B | 3.79B |
| Total Debt | 0.00 | 22.33B | 20.21B | 23.56B | 21.84B | 21.98B |
| Total Liabilities | -52.81B | 33.34B | 34.78B | 39.87B | 40.21B | 40.41B |
| Stockholders Equity | 52.81B | 49.40B | 43.53B | 33.59B | 33.54B | 38.49B |
Cash Flow | ||||||
| Free Cash Flow | 1.19B | 640.00M | -2.64B | 30.00M | -560.00M | 2.01B |
| Operating Cash Flow | 1.89B | 2.00B | -220.00M | 2.19B | 1.53B | 4.13B |
| Investing Cash Flow | -4.17B | -2.75B | -7.83B | -1.37B | -1.25B | -2.01B |
| Financing Cash Flow | 2.97B | 1.41B | 4.09B | 3.34B | -3.15B | -710.00M |
Wockhardt Limited Technical Analysis
Positive
1405.55
Price Trends
1914.13
Positive
1815.59
Positive
1581.04
Positive
Market Momentum
35.93
Negative
70.31
Negative
80.16
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WOCKPHARMA, the sentiment is Positive. The current price of 1405.55 is below the 20-day moving average (MA) of 1919.70, below the 50-day MA of 1914.13, and below the 200-day MA of 1581.04, indicating a bullish trend. The MACD of 35.93 indicates Negative momentum. The RSI at 70.31 is Negative, neither overbought nor oversold. The STOCH value of 80.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:WOCKPHARMA.
Wockhardt Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹432.91B | 38.09 | ― | 1.71% | 20.19% | 22.01% | |
71 Outperform | ₹498.47B | 38.06 | ― | 0.31% | 10.59% | 68.21% | |
69 Neutral | ₹365.84B | 36.10 | ― | 0.19% | 18.36% | 35.60% | |
66 Neutral | ₹620.78B | 28.79 | ― | 1.03% | 13.36% | -5.66% | |
66 Neutral | ₹684.96B | 38.25 | ― | 0.20% | 32.94% | 138.54% | |
58 Neutral | ₹339.07B | 83.35 | ― | 1.27% | 18.37% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:WOCKPHARMA
Wockhardt Limited
2,207.35
710.60
47.48%
IN:AJANTPHARM
Ajanta Pharma Limited
3,512.50
1,000.20
39.81%
IN:ALKEM
Alkem Laboratories Ltd.
5,180.00
-99.31
-1.88%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,927.15
544.68
39.40%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,462.00
353.03
16.74%
IN:IPCALAB
IPCA Laboratories Limited
1,959.15
644.62
49.04%
Wockhardt Limited Corporate Events
Wockhardt Publishes AGM Addendum Notice in Newspapers, Posts Extracts Online
Aug 7, 2026
Wockhardt Limited has issued an addendum to the notice of its 27th Annual General Meeting, and notified stock exchanges that the related public notice has been published in Business Standard (all-India edition) and Lokmat (Chhatrapati Sambhajinaga...
Wockhardt Publishes Statutory Notice for 27th AGM in National Dailies
Jul 3, 2026
Wockhardt Limited has notified shareholders that its 27th Annual General Meeting will be held in accordance with SEBI’s Listing Obligations and Disclosure Requirements, and has published the statutory public notice in two newspapers: Busines...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.